Clinical Trials on Spondylitis in Argentina

Total 35 results

Janssen Research & Development, LLC

Terminated

An Efficacy and Safety Study of Ustekinumab in Participants With Active Nonradiographic Axial Spondyloarthritis

Nonradiographic Axial Spondylitis, Ankylosing

Australia, France, Ukraine, United Kingdom, Belgium, Germany, Taiwan, Argentina, Mexico, Poland, Korea, Republic of, Russian Federation, Hungary, Czechia
Liga Panamericana de Asociaciones de Reumatologia...

Recruiting

PANLAR's Latin American Registry of Rheumatic Patients Treated With Jak Inhibitors (PREJAK)

Arthritis, Rheumatoid | Arthritis, Psoriatic | Spondyloarthritis

Argentina
Pfizer

Completed

Study Comparing Etanercept (ETN) Against a Placebo for Etanercept on a Background Nonsteroidal Anti Inflammatory Drug (NSAIDs) in the Treatment of Early Spondyloarthritis (SpA) Patients Who do Not Have X-ray Structural Changes (EMBARK)

Spondylitis, Ankylosing

Belgium, Korea, Republic of, Spain, France, Taiwan, Germany, Argentina, Czech Republic, United Kingdom, Hungary, Russian Federation, Colombia, Finland, Netherlands
Novartis Pharmaceuticals

Completed

Effect of Secukinumab on Radiographic Progression in Ankylosing Spondylitis as Compared to GP2017 (Adalimumab Biosimilar) (SURPASS)

Ankylosing Spondylitis

Taiwan, Netherlands, United Kingdom, Germany, Korea, Republic of, Israel, United States, Belgium, Greece, Philippines, Russian Federation, Spain, Turkey, Portugal, Mexico, Peru, Denmark, France, Czechia, Australia, Canada, Poland, J... and more
AstraZeneca

Completed

Prevalence Study of Gastrointestinal Risk Factors in Patients With Osteoarthritis (OA), Rheumatoid Arthritis (RA) and Ankylosing Spondylitis (AS). (RATIONAL)

Osteoarthritis (OA) | Rheumatoid Arthritis (RA) | Ankylosing Spondylitis (AS)

Mexico, Vietnam, Malaysia, Argentina, Philippines, Korea, Republic of, Venezuela, Colombia, Russian Federation, Thailand
Eli Lilly and Company

Withdrawn

Study of Ixekizumab in Participants With Active Ankylosing Spondylitis (AS) (SPIRIT A1)

Spondylitis, Ankylosing

Spain, United States, Hungary, Belgium, France, Mexico, Netherlands, Poland, Russian Federation, Ukraine, United Kingdom, Canada, Argentina, Germany, Czech Republic
Eli Lilly and Company

Completed

A Study of Ixekizumab (LY2439821) in TNF Inhibitor Experienced Participants With Radiographic Axial Spondyloarthritis (COAST-W)

Spondyloarthritis

Italy, Japan, United States, Puerto Rico, Spain, Mexico, Netherlands, France, Poland, Israel, Argentina, Brazil, Canada, Korea, Republic of, Germany, Finland, United Kingdom
CSL Behring

Completed

Psoriatic Arthritis Dose Ranging Study for BMS-945429 in Subjects Who Are Not Responding to NSAIDs or Non-biologic Disease Modifying Anti-rheumatic Drugs (DMARDs) Therapy

Arthritis, Psoriatic

Italy, United States, Canada, Mexico, Poland, Spain, Germany, Czechia, Russian Federation, Australia, South Africa, Argentina, Hungary
Eli Lilly and Company

Completed

A Study of Ixekizumab (LY2439821) in Participants With Nonradiographic Axial Spondyloarthritis (COAST-X)

Axial Spondyloarthritis

United States, Puerto Rico, Russian Federation, Mexico, Poland, Argentina, Austria, Brazil, Canada, Czechia, Finland, Germany, Japan, Korea, Republic of, Netherlands, Romania
Janssen Research & Development, LLC

Terminated

A Study to Evaluate the Efficacy and Safety of Ustekinumab in the Treatment of Anti-TNF(Alpha) Refractory Participants With Active Radiographic Axial Spondyloarthritis

Axial Spondyloarthritis

United States, Canada, France, Ukraine, United Kingdom, Belgium, Germany, Taiwan, Spain, Argentina, Mexico, Poland, Portugal, Bulgaria, Korea, Republic of, Brazil, Russian Federation, Hungary, Czechia
Bristol-Myers Squibb

Terminated

Safety and Efficacy of Abatacept Versus Placebo in Participants With Psoriatic Arthritis

Psoriatic Arthritis

Argentina, France, Italy, United States, Canada, Belgium, Netherlands, Australia, Germany, South Africa, Spain, Norway
Novartis Pharmaceuticals

Completed

Study of Power Doppler Ultrasound (PDUS) to Measure Response of Secukinumab Treatment in Patients With Active Psoriatic Arthritis (PsA) (PDUS)

Psoriatic Arthritis

Germany, Netherlands, Spain, Argentina, Belgium, Colombia, Italy, United States, United Kingdom, Ireland, France, Mexico, Canada, Austria, Czechia, Hungary, Norway
UCB BIOSCIENCES GmbH

Completed

Certolizumab Pegol in Subjects With Active Axial Spondyloarthritis

Spondyloarthropathies

Germany, United States, Argentina, Belgium, Brazil, Canada, Czechia, France, Hungary, Italy, Mexico, Poland, Spain, United Kingdom, Netherlands
AbbVie

Active, not recruiting

A Study to Evaluate Efficacy and Safety of Upadacitinib in Adults With Axial Spondyloarthritis (SELECT-AXIS 2)

Spondyloarthritis

United States, Argentina, Australia, Belgium, Brazil, Bulgaria, Canada, China, Czechia, France, Germany, Hungary, Israel, Japan, Korea, Republic of, Mexico, New Zealand, Poland, Russian Federation, Slovakia, Spain, Taiwan, Turkey, Ukr... and more
Eli Lilly and Company

Completed

A Long Term Extension Study of Ixekizumab (LY2439821) in Participants With Axial Spondyloarthritis

Axial Spondyloarthritis

United States, Puerto Rico, Korea, Republic of, Netherlands, Taiwan, Canada, Israel, Spain, Japan, Brazil, Argentina, Hungary, Poland, Czechia, France, Russian Federation, Germany, Mexico, United Kingdom, Romania, Italy, Finland, Au...
AbbVie

Active, not recruiting

A Study of the Change in Early and Sustained Pain Control in Axial Spondylarthritis in Adult Participants Receiving Upadacitinib (UPSTAND)

Axial Spondylarthritis (axSpA)

Argentina, Australia, Belgium, Bulgaria, Canada, France, Greece, Hungary, Israel, Kuwait, Mexico, Poland, Russian Federation, Spain, Switzerland, United Arab Emirates
Sun Pharmaceutical Industries Limited

Completed

Long-Term Extension Trial of Tildrakizumab to Prove Its Safety in Subjects With Psoriatic Arthritis Who Have Previously Completed Study With Tildrakizumab.

Psoriatic Arthritis

United States, Argentina, Hungary, Mexico, Poland, Russian Federation, Spain, Ukraine
UCB BIOSCIENCES GmbH

Completed

Certolizumab Pegol in Subjects With Adult Onset Active and Progressive Psoriatic Arthritis

Arthritis, Psoriatic

Germany, United States, Argentina, Belgium, Brazil, Canada, Czechia, France, Hungary, Ireland, Italy, Mexico, Poland, Spain, United Kingdom
Janssen Pharmaceutica N.V., Belgium

Recruiting

A Study of Guselkumab and Interleukin-17 (IL-17) Inhibitor Therapies in Participants With Psoriatic Arthritis in Routine Clinical Practice (PsABIOnd)

Arthritis, Psoriatic

Belgium, Korea, Republic of, Austria, Germany, Japan, Mexico, Greece, United Kingdom, Italy, Sweden, Spain, France, Taiwan, Netherlands, Canada, Argentina, Australia, Colombia, Russian Federation, Switzerland
Janssen Research & Development, LLC

Recruiting

A Long-term Extension Study of Ustekinumab in Pediatric Participants (UNITED)

Crohn Disease | Arthritis, Psoriatic | Colitis, Ulcerative

Belgium, France, United States, Hungary, Japan, United Kingdom, Germany, Poland, Argentina
Bristol-Myers Squibb

Completed

Efficacy and Safety of Subcutaneous Abatacept in Adults With Active Psoriatic Arthritis (ASTRAEA)

Psoriatic Arthritis

Italy, South Africa, United States, Spain, Germany, Mexico, Israel, France, Greece, Canada, Brazil, Czechia, Peru, Poland, Argentina, Colombia, Chile
Novartis Pharmaceuticals

Completed

Efficacy at 24 Weeks and Long Term Safety, Tolerability and Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Psoriatic Arthritis (PsA) (FUTURE 1)

Psoriatic Arthritis

Germany, United Kingdom, United States, Belgium, Philippines, Singapore, Thailand, Brazil, Czech Republic, Italy, Argentina, Israel, Russian Federation, Bulgaria, Romania, Australia, Canada, Poland, Slovakia
Novartis Pharmaceuticals

Completed

Extension Study up to 3 Years for Secukinumab in Psoriatic Arthritis (FUTURE 1 ext)

Psoriatic Arthritis

United Kingdom, Belgium, Germany, Thailand, Israel, United States, Philippines, Singapore, Italy, Argentina, Russian Federation, Bulgaria, Czechia, Australia, Canada, Poland, Brazil, Slovakia
Janssen Research & Development, LLC

Recruiting

A Study of Guselkumab Administered Subcutaneously in Bio-naive Participants With Active Psoriatic Arthritis Axial Disease (STAR)

Arthritis, Psoriatic

Italy, Germany, Taiwan, United States, Malaysia, Turkey, Georgia, Canada, Hong Kong, Portugal, Denmark, Israel, Philippines, Thailand, Bulgaria, Australia, Czechia, Hungary, Poland, Russian Federation, Ukraine, Spain, Argentina, United... and more
Janssen Research & Development, LLC

Recruiting

A Study of Ustekinumab or Guselkumab in Pediatric Participants With Active Juvenile Psoriatic Arthritis (PSUMMIT-Jr)

Arthritis, Juvenile

United States, France, United Kingdom, Turkey, Spain, Argentina, Germany, Italy, Poland, Denmark
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Study Evaluating Etanercept on Skin and Joint Disease in Psoriatic Arthritis

Psoriatic Arthritis

France, Belgium, Korea, Republic of, Netherlands, United Kingdom, Germany, Taiwan, Portugal, Denmark, Saudi Arabia, Czechia, Sweden, Switzerland, Argentina, Poland, Italy, Hungary, Spain, Australia, Austria, Colombia, Finland, Former... and more
Bristol-Myers Squibb

Active, not recruiting

A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Naïve to Biologic Disease Modifying Anti-rheumatic Drugs or Had Previously Received TNFα Inhibitor Treatment

Psoriatic Arthritis

United States, Australia, Belgium, Spain, Argentina, China, Canada, Colombia, Czechia, Germany, Hungary, Italy, Japan, Mexico, Poland, Russian Federation, Taiwan, United Kingdom
Eli Lilly and Company

Completed

A Study of Ixekizumab (LY2439821) Versus Adalimumab in Participants With Psoriatic Arthritis (SPIRIT-H2H)

Psoriatic Arthritis

Belgium, Hungary, Canada, India, Israel, Italy, Australia, Netherlands, United Kingdom, Mexico, Switzerland, South Africa, Poland, Finland, Argentina, France, Germany, Ukraine, Spain, Austria, Denmark, Sweden
Amgen

Completed

Etanercept and Methotrexate in Combination or as Monotherapy in Psoriatic Arthritis

Psoriatic Arthritis

United States, Hungary, Czechia, Mexico, Russian Federation, Puerto Rico, Canada, Greece, Poland, Bulgaria, Spain, United Kingdom, Argentina, Latvia, Chile, France, Portugal, South Africa
Janssen Research & Development, LLC

Recruiting

Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha Agent (SOLSTICE)

Arthritis, Psoriatic

Israel, Turkey, United States, Hungary, Spain, Australia, Bulgaria, Czechia, Malaysia, Poland, Puerto Rico, Russian Federation, Ukraine, Argentina
Novartis Pharmaceuticals

Completed

Study to Demonstrate the Efficacy (Including Inhibition of Structural Damage), Safety and Tolerability up to 2 Years of Secukinumab in Active Psoriatic Arthritis (FUTURE5)

Psoriatic Arthritis

United States, United Kingdom, India, Austria, Denmark, Netherlands, Spain, Germany, Thailand, Israel, Argentina, Greece, Philippines, Latvia, Italy, Guatemala, Russian Federation, Hungary, Ireland, Vietnam, Czechia, Canada, Sweden, M... and more
AbbVie

Active, not recruiting

A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy (KEEPsAKE 1)

Psoriatic Arthritis

United States, Argentina, Australia, Belgium, Bosnia and Herzegovina, Brazil, Bulgaria, Canada, Chile, Croatia, Czechia, Denmark, Estonia, Finland, Germany, Greece, Israel, Italy, Korea, Republic of, Latvia, Lithuania, Malaysia, Mexico and more
AbbVie

Active, not recruiting

A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies) (KEEPsAKE2)

Psoriatic Arthritis (PsA)

United States, Argentina, Australia, Belgium, Brazil, Canada, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Israel, Italy, Netherlands, New Zealand, Poland, Portugal, Puerto Rico, Singapore, South Africa, Spain, Sweden, United...
Bristol-Myers Squibb

Recruiting

A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Naïve to Biologic Disease-modifying Anti-rheumatic Drugs

Psoriatic Arthritis

Italy, United States, Australia, Argentina, Brazil, Czechia, France, Hungary, Mexico, Russian Federation, China, Poland, Finland, Colombia, United Kingdom, Bulgaria, Taiwan, Chile, Romania, Spain, Ireland
AbbVie

Active, not recruiting

A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Participants With Psoriatic Arthritis Who Have an Inadequate Response to at Least One Non-Biologic Disease Modifying Anti-Rheumatic Drug (DMARD) (SELECT - PsA 1)

Psoriatic Arthritis

United States, Argentina, Australia, Belarus, Belgium, Bosnia and Herzegovina, Brazil, Bulgaria, Canada, Chile, China, Colombia, Croatia, Czechia, Estonia, Germany, Greece, Hong Kong, Hungary, Ireland, Israel, Italy, Japan, Korea, Republic... and more

Clinical Trials on Spondylitis in Argentina

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Sweden

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations